Cargando…
The endothelin B (ET(B)) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification
The vascular effects of the endothelin B (ET(B)) receptor agonist IRL 1620 were investigated in the rat P22 carcinosarcoma and a range of normal tissues in BDIX rats. Tissue blood flow rate was calculated from measurements of tissue uptake of radiolabelled iodoantipyrine. A comparison of vascular ef...
Autores principales: | Cemazar, M, Wilson, I, Prise, V E, Bell, K M, Hill, S A, Tozer, G M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361472/ https://www.ncbi.nlm.nih.gov/pubmed/15970923 http://dx.doi.org/10.1038/sj.bjc.6602672 |
Ejemplares similares
-
Neuroprotective Effect of IRL-1620, an Endothelin B Receptor Agonist, on a Pediatric Rat Model of Middle Cerebral Artery Occlusion
por: Cifuentes, Enrique G., et al.
Publicado: (2018) -
Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008) -
Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
por: Lindner, D, et al.
Publicado: (2009) -
Anti-apoptotic activity of ET(B) receptor agonist, IRL-1620, protects neural cells in rats with cerebral ischemia
por: Briyal, Seema, et al.
Publicado: (2019) -
Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)